Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH Clinical Practice Guidelines Prevention and Management of Dermatological Toxicities Related to Anticancer Agents, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. We found a higher incidence of carboplatin-related hypersensitivity among patients with advanced disease (stage IIIIV) with serous carcinoma and malignant ascites. Our findings also suggest that a history of drug or food allergies is a predictive factor for carboplatin-related hypersensitivity. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. Carboplatin and other paltins, Algorithm for the evaluation of drug hypersensitivity reactions and the role of desensitization. Please enable it to take advantage of the complete set of features! Carboplatin and pegylated liposomal doxorubicin (Pujade-Lauraine et al., 2010) or gemcitabine (Pfisterer et al., 2006) led to superior progression-free survival of patients with platinum-sensitive recurrent ovarian cancer compared to paclitaxel and carboplatin. 2012;97:217-33. doi: 10.1159/000335637. This site uses cookies. 84, 378382. Acquisition of data: Y-HT, S-PL, Y-CC, Y-LC. The annual ESMO Congress is the most prestigious and influential oncology platform in Europe and is the ideal place to learn about the latest science, network with colleagues and keep pace with today's rapid developments in cancer research. We analyzed the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions among these patients. There is a need to further characterise risk of anaphylaxis/hypersensitivity with PH IV/PH FDC SC to support safe administration outside of clinics. doi: 10.1007/s00520-011-1123-y, Gomez, R., Harter, P., Lck, H. J., Traut, A., Kommoss, S., Kandel, M., et al. (Moon et al., 2013) BRCA1/2 mutation patients had early-onset carboplatin hypersensitivity at a lower cumulative exposure. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Multistep IgE Mast Cell Desensitization Is a Dose- and Time-Dependent Process Partially Regulated by SHIP-1. Accessibility A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., Sessa, C., et al. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. doi: 10.1093/annonc/mdx216. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. 105, 8183. official website and that any information you provide is encrypted Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. J. Gynecol. (2016). Successful carboplatin desensitization in patients with proven carboplatin allergy. PDF Management of Immune-related Adverse Events in Patients Treated - Asco Timetrend analyses showed that most events were reported during the first 68 cycles with concurrent chemotherapy, with a decrease in later cycles (except MetaPHER). Parmar et al. (2005) reported that all carboplatin-associated hypersensitivity reactions occur in patients with prior carboplatin exposure, and Tamiya et al. Genc et al. Tyler T, Schultz A, Venturini A, Giuliano C, Bernareggi A, Spezia R, Voisin D, Stella V. Clin Pharmacol Drug Dev. All accepted abstracts are available in theESMO 2017 Abstract Book. Methods. doi: 10.1007/s00280-009-1159-6, Iwamoto, T., Hirai, H., Yamaguchi, N., Kobayashi, N., Sugimoto, H., and Tabata, T. (2014). -, A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Our results revealed carboplatin-related hypersensitivity reactions in 1 out of 10 women treated with a carboplatin-containing regimen for ovarian, fallopian tube, or primary peritoneal cancer. 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. 66, 730. doi: 10.1038/bjc.2013.389, Navo, M., Kunthur, A., Badell, M. L., Coffer, L. W. ESMO Virtual Congress 2020 | OncologyPRO This site uses cookies. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. (2009). Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. ESMO Colloquia are innovative sessions within the Congress programme, organised by ESMO and supported by industry, Information about the exhibition and Satellite Symposia, Contact details and welcome message, plus other general information about ESMO 2017. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. 24, 46994707. Therefore, the preferred regimen for platinum-sensitive recurrent ovarian cancer is carboplatin combined with paclitaxel, liposomal doxorubicin, or gemcitabine. (2003). Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. (PDF) Management of cancer pain in adult patients: ESMO Clinical 2023 Jan 23;11(2):252. doi: 10.3390/vaccines11020252. Several methods have been developed to prevent carboplatin-related hypersensitivity reactions (Libra et al., 2003; Confino-Cohen et al., 2005; Gomez et al., 2009; Greene et al., 2010; Takase et al., 2015; Shah et al., 2016). Lacouture, V. Sibaud, P.A. Ann Oncol. This site uses cookies. Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. One-fifth of these patients never attempt carboplatin reinfusion, even after only mild hypersensitivity reactions (Gadducci et al., 2008). The most commonly exhibited symptom/sign was hypotension (10.7%), followed by anaphylaxis (8.0%) and desaturation (6.7%). However, 48 (78.7%) of these patients developed repeated hypersensitivity reactions, even after pre-treatment with intravenous antihistamines, H2 blocker, and corticosteroids prior to carboplatin re-administration. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. government site. Received: 23 July 2017; Accepted: 23 October 2017; Published: 06 November 2017. (Markman, 2007) reported that carboplatin-related hypersensitivity reactions rarely occur before cycle 6 or <3,000 mg of drug delivery, with the first episode most commonly occurring with carboplatin administration in the second-line setting, and carboplatin administration beyond 9 cycles or 6,000 mg increasing the risk of severe hypersensitivity reactions, similar to our present observations. 66, 265267. A video magazine about the congress, highlighting the most important information about the event. Necessary cookies enable core functionality. Assess for pustules or blisters or erosions in addition to areas of "dusky erythema" which may feel painful to palpation. The rate of hypersensitivity to carboplatin did not differ by patient age, menopausal status, disease entity, receipt of optimal debulking, or the amount of ascites. Nitipir C, Parosanu A, Popa AM, Cotan H, Olaru M, Iaciu C, Orlov Slavu C. Cureus. Swain: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Advisory Role: Exact Sciences (Genomic Health); Financial Interests, Personal, Advisory Role: Molecular Templates; Financial Interests, Personal, Advisory Role: Silverback Therapeutics; Financial Interests, Personal, Advisory Role: Tocagen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Natera; Financial Interests, Personal, Advisory Role: Beijing Medical Foundation; Financial Interests, Personal, Advisory Board: Inivata; Financial Interests, Personal, Research Grant: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Research Grant: KailosGenetics; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: BMS; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Lilly; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: F. Hoffmann-La Roche Ltd./Genentech, Inc.; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Daiichi-Sankyo; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Caris Life Sciences; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Tan: Non-Financial Interests, Institutional, Research Grant: Genentech/Roche; Non-Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Personal, Advisory Board: Genentech; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Immunomedics; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Athenex; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Merck; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. L. Gianni: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: ADC Therapeutics; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Celgene; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: G1 Therapeutics; Financial Interests, Personal, Advisory Board: Genentech, Inc.; Financial Interests, Personal, Advisory Board: Genomic Health; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Oncolytics Biotech; Financial Interests, Personal, Advisory Board: Odonate Therapeutics; Financial Interests, Personal, Advisory Board: Onkaido Therapeutics; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Taiho Pharmaceutical; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: Synthon and Zymeworks; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Zymeworks; Financial Interests, Institutional, Research Grant: Revolution Medicines; Financial Interests, Personal, Advisory Role: Forty Seven; Financial Interests, Personal, Advisory Role: Metis Precision Medicine; Financial Interests, Personal, Advisory Role: Menarini Ricerche; Financial Interests, Personal, Advisory Role: Synaffix; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Revolution Medicines; Non-Financial Interests, Personal, Other, Patent; EPA 12195182.6 12196177.5-Roche, pending (coinventor): Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Kmmel: Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Genomic Health; Financial Interests, Personal, Advisory Role: Exact Science; Financial Interests, Personal, Advisory Role: Seagen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Daiichi Sanyko; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: Somatex; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: PFM medical; Financial Interests, Personal, Advisory Role: Lily; Non-Financial Interests, Personal, Other: Roche; Non-Financial Interests, Personal, Other: Daiichi Sankyo; Non-Financial Interests, Personal, Other: Lily; Non-Financial Interests, Personal, Other: Sonoscape; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Dang: Financial Interests, Personal, Other, Honoraria: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Other, Honoraria: Genentech, Inc.; Financial Interests, Personal, Other, Honoraria: Daiichi-Sankyo; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Other, Honoraria: Puma Biotechnology; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. A. Schneeweiss: Financial Interests, Institutional, Research Grant: Celgene; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Institutional, Research Grant: AbbVie; Financial Interests, Personal, Expert Testimony: Roche; Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Other, Travel expenses: Celgene; Financial Interests, Personal, Other, Travel expenses: Roche; Financial Interests, Personal, Other, Honoraria: Roche; Financial Interests, Personal, Other, Honoraria: Celgene; Financial Interests, Personal, Other, Honoraria: Pfizer; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Other, Honoraria: Novartis; Financial Interests, Personal, Other, Honoraria: MSD; Financial Interests, Personal, Other, Honoraria: Tesaro; Financial Interests, Personal, Other, Honoraria: Lily; Financial Interests, Personal, Other, Travel expenses: Pfizer; Financial Interests, Personal, Other, Honoraria: Seagen; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. J. O'Shaughnessy: Financial Interests, Personal, Advisory Role: AbbVie; Financial Interests, Personal, Advisory Role: Agendia; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Celgene; Financial Interests, Personal, Advisory Role: Eisai; Financial Interests, Personal, Advisory Role: Genentech, Inc.; Financial Interests, Personal, Advisory Role: Immunomedics; Financial Interests, Personal, Advisory Role: Ipsen; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: Merck; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: Odonate; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Advisory Role: Puma; Financial Interests, Personal, Advisory Role: Prime Oncology; Financial Interests, Personal, Advisory Role: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Advisory Role: Seattle Genetics; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. C. Aguila: Financial Interests, Personal, Full or part-time Employment, Clinical Scientist/Medical Director: F. Hoffmann-La Roche Ltd.; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Heeson: Financial Interests, Personal, Full or part-time Employment: Roche Products Ltd.; Financial Interests, Personal, Stocks/Shares: Roche Products Ltd.; Non-Financial Interests, Personal, Other, Patent; PH FDC SC: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. H. Macharia: Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Full or part-time Employment: F. Hoffman-La Roche. doi: 10.1111/cas.12538, Kandel, M. J., Loehr, A., Harter, P., Traut, A., Gnauert, K., and du Bois, A. Department of Pharmacological and Biomolecular Sciences, Faculty of Pharmacy, University of Milan, Italy, Ospedale Oncologico Armando Businco, Italy, University of Arkansas for Medical Sciences, United States. reported that the majority (93%) of patients with a BRCA1/2 mutation develop carboplatin hypersensitivity, and that BRCA1/2 mutation is an independent risk factor for the development of carboplatin hypersensitivity. We assessed occurrence, incidence and severity of these events in key Roche clinical trials of PH IV/PH FDC SC, and did a timetrend analysis (by cycle) for metastatic BC (MBC) and early BC (EBC) studies. For more detailed information on the cookies we use, please check our Privacy Policy. doi: 10.3322/caac.21332, Sliesoraitis, S., and Chikhale, P. J. The overall safety profile was similar between subgroups. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Although infusion reactions can be allergic or non-immune-mediated, the clinical manifestations are the same and require prompt assessment and appropriate intervention. The yearly incidence of carboplatin-related hypersensitivity gradually increased from 0.88 in 2006 to 5.42% in 2013 (Table 1), in association with increased use of carboplatin. Oncol. 8600 Rockville Pike 2022 Apr 26;14(4):e24515. Prior to an infusion of a mAb, nurses should do the following (Olsen et al., 2019): . (2003) reported that paclitaxel with platinum improves overall survival compared to conventional platinum-based chemotherapy among patients with relapsed platinum-sensitive ovarian cancer. E. Restuccia: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: Genentech, Inc; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd. S. Loibl: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: AbbVie; Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Advisory Board: Celgene; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Seattle Genetics; Financial Interests, Institutional, Advisory Board: PriME/ Medscape; Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Research Grant: Teva; Financial Interests, Personal, Research Grant: Vifor; Financial Interests, Institutional, Research Grant: Daiichi-Sankyo; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: Samsung; Financial Interests, Institutional, Advisory Board: Eirgenix; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Puma; Financial Interests, Personal, Research Grant: Immunomedics; Non-Financial Interests, Personal, Other, Patent EP14153692 .0 pending: Roche; Non-Financial Interests, Personal, Research Grant, Medical writing support: F. Hoffmann-La Roche Ltd.; Financial Interests, Institutional, Advisory Board: MSD. Zhi. MeSH Gynecol. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . doi: 10.1111/j.1048-891x.2005.14401.x, Takase, N., Matsumoto, K., Onoe, T., Kitao, A., Tanioka, M., Kikukawa, Y., et al. and transmitted securely. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Check the latest publications and updates here to make sure you dont miss anything. Before (2010). Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. The rate of hypersensitivity was significantly higher among patients with advanced stage disease (IIIIV) compared to patients with early stage disease (III) (P < 0.001, Kruskal-Wallis test), and among patients with serous or mixed histological type compared to patients with other histological types (P = 0.003, Kruskal-Wallis test). Here, we retrospectively evaluated carboplatin-related hypersensitivity reactions among patients with gynecological cancer (ovarian, fallopian tube, or primary peritoneal cancer) who received carboplatin-containing regimens at a single medical institute in Taiwan. eCollection 2022. Gynecol. Unauthorized use of these marks is strictly prohibited. Cancer 15, 1318. The BRCA status of our patients was not available for further analysis in this retrospective study.